{"id":38567,"date":"2015-12-17T09:40:31","date_gmt":"2015-12-17T14:40:31","guid":{"rendered":"http:\/\/asweetlife.org\/?post_type=feature&#038;p=38567"},"modified":"2016-07-03T03:11:16","modified_gmt":"2016-07-03T07:11:16","slug":"7-new-diabetes-products-to-look-for-in-2016","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=38567","title":{"rendered":"7 New Diabetes Products to Look for in 2016"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/feature\/7-new-diabetes-products-to-look-for-in-2015\/\">As we predicted<\/a> last December, 2015 saw the release of the Dexcom G4 Platinum with Share receiver, the Tandem t:slim G4 insulin pump, the Dexcom G5 Continuous Glucose Monitoring System, the Medtronic 640G with SmartGuard in Europe, and two novel new insulins (both from Sanofi) \u2013 Afrezza inhalable short-acting and Toujeo basal insulin. Also launched in 2015 were Eli Lilly\u2019s Trulicity GLP-1 agonist and Novo Nordisk\u2019s Tresiba basal insulin.<\/p>\n<p style=\"text-align: justify;\"><strong>Looking ahead to 2016, we\u2019re optimistic about these seven diabetes products potentially hitting the market in the next 12 months.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>\u00a0<\/strong><\/p>\n<h2 style=\"text-align: justify;\"><strong>Insulet\u2019s Omnipod Phoenix PDM Insulin Pump<\/strong><\/h2>\n<figure id=\"attachment_38579\" aria-describedby=\"caption-attachment-38579\" style=\"width: 289px\" class=\"wp-caption alignleft\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/OmniPodPDM.jpeg\" rel=\"mfp\"><img decoding=\"async\" class=\"wp-image-38579 size-medium lazyload\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/OmniPodPDM-289x300.jpeg\" alt=\"Insulet\u2019s Omnipod Phoenix PDM Insulin Pump\" width=\"289\" height=\"300\" data-sizes=\"auto\" data-srcset=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/OmniPodPDM-289x300.jpeg 289w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/OmniPodPDM.jpeg 459w\" sizes=\"(max-width: 289px) 100vw, 289px\" \/><\/a><figcaption id=\"caption-attachment-38579\" class=\"wp-caption-text\">Photo courtesy of Diabetes Mine<\/figcaption><\/figure>\n<p style=\"text-align: justify;\">At the ADA Scientific Sessions in Boston this June, Insulet teased the crowd with a <a href=\"http:\/\/www.healthline.com\/diabetesmine\/diabetes-tech-update-mid-2015-and-beyond\" target=\"_blank\">first look<\/a> at the next generation controller for their popular patch insulin pump, the Phoenix PDM (Personal Diabetes Manager). The chunky plastic PDM controllers we saw in the UST200 and UST400 models will give way to a sleek, sexy color touchscreen interface. The Phoenix will be thinner than the UST400, black in color, and resemble a smartphone. Though the Phoenix will be Bluetooth-enabled, this PDM will not yet be integrated with the Dexcom G5, though we should see that product quickly on its coattails given that value-added capability.<\/p>\n<p style=\"text-align: justify;\">When might we see the Phoenix rise? In their <a href=\"http:\/\/seekingalpha.com\/article\/3654716-insulet-podd-patrick-j-sullivan-on-q3-2015-results-earnings-call-transcript?part=single\" target=\"_blank\">Q3 earnings call<\/a> on 5 November, Insulet CEO Patrick Sullivan said they are \u201con track to submit our Phoenix PDM product to the FDA in the middle of next year, and we would expect to have that on the market or approved by the end of next year.\u201d<\/p>\n<h2 style=\"text-align: justify;\"><strong>Abbott Freestyle Libre Pro Flash Glucose Monitoring System (U.S.)<\/strong><\/h2>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/5_abtt.jpg\" rel=\"mfp\"><img decoding=\"async\" class=\"aligncenter wp-image-38568 lazyload\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/5_abtt.jpg\" alt=\"Abbott Freestyle Libre Pro Flash Glucose Monitoring System (U.S.)\" width=\"600\" height=\"218\" data-sizes=\"auto\" data-srcset=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/5_abtt.jpg 1600w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/5_abtt-300x109.jpg 300w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/5_abtt-1024x371.jpg 1024w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/5_abtt-768x278.jpg 768w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/5_abtt-1536x557.jpg 1536w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/5_abtt-600x218.jpg 600w\" sizes=\"(max-width: 600px) 100vw, 600px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">The <a href=\"https:\/\/abbottdiabetescare.co.uk\/our-products\/freestyle-libre\" target=\"_blank\">Freestyle Libre<\/a> (consumer version) and Libre Pro (professional HCP-use version) might flash their way stateside in 2016. The first of its kind, the Libre is a factory-calibrated flash system, which means that, rather than continuous display of interstitial glucose readings, the user wears a small sensor in the skin beneath a flat, round, white, disc-shaped transmitter and carries (in the consumer version) a small device that the person can use to scan the sensor and display a reading at any time. Demand has been so high in Europe that consumers report a significant backorder.<\/p>\n<p style=\"text-align: justify;\">Libre\u2019s appearance in the Freestyle pipeline follows Abbott\u2019s long commitment toward out-of-the-box calibration and this author believes it serves as an important proof of concept toward their next generation continuous glucose sensors. (I used their gen1 Freestyle Navigator CGMS for three years and was a big fan.) Our hope here is that Libre paves the way for continued progress in CGM technology from the company.<\/p>\n<p style=\"text-align: justify;\">While Abbott has been tight-lipped about progress to bring Libre to the United States, we do know that the Libre Pro has been submitted to the FDA for potential launch in 2016. The Pro version is meant to be used by health care providers to collect glucose data \u2013 which is blinded to the patient \u2013 for analysis and treatment changes and would have an easier pathway for reimbursement than the consumer version. As for Libre for home use, we\u2019re still betting here on 2017, though the <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02283411?term=diabetes+and+devices&amp;recr=Open&amp;rank=6\" target=\"_blank\">pivotal study<\/a> of Libre in the United States was completed in March 2015. Abbott has not historically had the kind of smooth, fast-track relationship with FDA that companies like Dexcom have mastered.<\/p>\n<h2 style=\"text-align: justify;\">\u00a0<\/h2>\n<h2 style=\"text-align: justify;\"><strong>Medtronic Minimed 640G Insulin Pump (U.S.)<\/strong><\/h2>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/medtronic640G.jpg\" rel=\"mfp\"><img decoding=\"async\" class=\"aligncenter wp-image-38571 size-full lazyload\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/medtronic640G.jpg\" alt=\"Medtronic Minimed 640G Insulin Pump\" width=\"520\" height=\"287\" data-sizes=\"auto\" data-srcset=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/medtronic640G.jpg 520w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/medtronic640G-300x166.jpg 300w\" sizes=\"(max-width: 520px) 100vw, 520px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">The Minimed 640G insulin pump may come to the States by end-of-year 2016, as Medtronic says they plan to submit to FDA early in the new year.<\/p>\n<p style=\"text-align: justify;\">Building on the success of their Low Glucose Suspend (LGS) feature in the 530G model (called Minimed Veo outside the U.S.), the 640G adds <em>predictive<\/em> LGS capabilities (called SmartGuard abroad) and can suspend and resume basal delivery based on predicted hypos, performing as a semi-automatic closed loop. This is the most revolutionary change in design we\u2019ve seen from Medtronic, with a whole new colored user interface, new buttons, and a portrait orientation \u2013 shifting the long-standing insulin pump paradigm from pager to smartphone.<\/p>\n<p style=\"text-align: justify;\">The pivotal trial in the States was completed with Medtronic\u2019s fourth generation sensor (the third in the Enlite series) and they <a href=\"https:\/\/fccid.io\/document.php?id=2541470\" target=\"_blank\">submitted specs<\/a> to the FCC in February for a transmitter designed specifically for the 600 series pumps (of which 670G will be the next in their pipeline), so we expect to see Medtronic skip the Enlite 2 here in the U.S. entirely and move to this fourth generation sensor in the 640G when it comes to the United States.<\/p>\n<h2 style=\"text-align: justify;\"><strong>Dexcom 6 Continuous Glucose Monitoring System<\/strong><\/h2>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/Dexcom-iphone-g5-transmitter_0.jpg\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft wp-image-38575 size-medium lazyload\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/Dexcom-iphone-g5-transmitter_0-281x300.jpg\" alt=\"Dexcom - iphone-g5-transmitter\" width=\"281\" height=\"300\" data-sizes=\"auto\" data-srcset=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/Dexcom-iphone-g5-transmitter_0-281x300.jpg 281w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/Dexcom-iphone-g5-transmitter_0-961x1024.jpg 961w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/Dexcom-iphone-g5-transmitter_0-768x819.jpg 768w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/Dexcom-iphone-g5-transmitter_0-600x640.jpg 600w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/Dexcom-iphone-g5-transmitter_0.jpg 1000w\" sizes=\"(max-width: 281px) 100vw, 281px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">It wouldn\u2019t be the end of a fiscal year without some speculation on what Dexcom has up its sleeves. If 2015 was the year of the Dex \u2013 with two integrated pump partners (Tandem and Animas) and two new products (G4 Platinum with Share and G5), then 2016 is going to be about their building capacity for what\u2019s to come. We\u2019re not going to see them rush too quickly toward G6 approval, especially as G6 supposedly will not require calibration, as <a href=\"http:\/\/seekingalpha.com\/article\/3647796-dexcom-dxcm-q3-2015-results-earnings-call-transcript?part=single\" target=\"_blank\">Kevin Sayer has said<\/a> that they have \u201cno intention of ever moving backwards from a non-injunctive claim once we establish it.\u201d<\/p>\n<p style=\"text-align: justify;\">Still, we know that Dexcom surprises even themselves with how quickly they can get product approved and rolled out to customers, with the original G4 Platinum approved within 90 days of submission to FDA. In the meantime, we expect to see a new insertion device for their sensors and hope to learn more about the G5 strengths and opportunities as the long line of customers waiting for Santa Claus to bring them their G5 systems unwrap those tech goodies.<\/p>\n<h2 style=\"text-align: justify;\"><strong>GLP-1 and GLP-1\/Basal Combos: Lyxumia, Lixilan, &amp; Xultophy<\/strong><\/h2>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/lyxumia.jpg\" rel=\"mfp\"><img decoding=\"async\" class=\"aligncenter size-full wp-image-38570 lazyload\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/lyxumia.jpg\" alt=\"lyxumia\" width=\"590\" height=\"300\" data-sizes=\"auto\" data-srcset=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/lyxumia.jpg 590w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/lyxumia-300x153.jpg 300w\" sizes=\"(max-width: 590px) 100vw, 590px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">Sanofi, having brought two new drugs to the US market in 2015 with Mannkind\u2019s Afrezza and their new basal Toujeo, is quickly working to follow that up with their GLP-1 agonist and GLP-1\/basal insulin combination drugs in the United States. Sanofi <a href=\"http:\/\/www.drugs.com\/nda\/lyxumia_150929.html\">filed for New Drug Appliaction<\/a> (NDA) with FDA for its GLP-1 agonist Lyxumia (lixisenatide) in September 2015. Once approved, we expect approval for Lixilan (Lyxumia+Lantus) to be right on its heels.<\/p>\n<p style=\"text-align: justify;\">Combination drugs are certainly a big market in type 2 therapies right now. Novo Nordisk\u2019s Xultophy, a combination of their commercially successful GLP-1 agonist Victoza and their brand new basal insulin Tresiba, also had its <a href=\"http:\/\/www.epgonline.org\/news\/novo-nordisk-files-nda-at-fda-for-xultophy-combination.cfm\">NDA put in front of FDA<\/a> in September and will likely beat Lixilan to market. Xultophy is already approved in Europe, but was held up here until its Tresiba component could be approved. We expect to see all three of these GLP-1 drugs available in pharmacies by next year\u2019s end.<\/p>\n<h2 style=\"text-align: justify;\"><strong>Novo\u2019s New Novolog and a Long-Acting from Lilly<\/strong><\/h2>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/novolog_flexpen.jpg\" rel=\"mfp\"><img decoding=\"async\" class=\"aligncenter wp-image-38572 lazyload\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/novolog_flexpen-e1450343458996.jpg\" alt=\"Novo Nordisk\u2019s New Novolog\" width=\"600\" height=\"331\" data-sizes=\"auto\" data-srcset=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/novolog_flexpen-e1450343458996.jpg 864w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/novolog_flexpen-e1450343458996-300x166.jpg 300w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/novolog_flexpen-e1450343458996-768x424.jpg 768w, https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/novolog_flexpen-e1450343458996-600x331.jpg 600w\" sizes=\"(max-width: 600px) 100vw, 600px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">Novo Nordisk has another game-changer up its sleeve, as well, having announced just last week that an NDA has been filed for a <a href=\"http:\/\/www.prnewswire.com\/news-releases\/novo-nordisk-files-for-regulatory-approval-of-faster-acting-insulin-aspart-in-the-us-300190405.html\" target=\"_blank\">newer, speedier version of Novolog<\/a> (insulin aspart) for treatment of type 1 and type 2 diabetes. According to their press release, the \u201cfaster-acting insulin aspart contains a short-acting insulin and two well-known excipients, a vitamin and an amino acid, to increase the initial absorption rate and an earlier blood sugar lowering effect.\u201d What does this mean for people with diabetes? Better post-prandial (post-meal) blood glucose control. Bring it on.<\/p>\n<p style=\"text-align: justify;\">Another insulin coming to us in 2016 is Lilly\u2019s new basal insulin, Basaglar \u2013 a form of insulin glargine (which you may recognize if you\u2019re familiar with Lantus). FDA approved it <a href=\"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm477734.htm\" target=\"_blank\">just this week<\/a> after a patent dispute was finally resolved with Sanofi. As stated in the FDA press release, \u201cBasaglar is the first insulin product approved through an abbreviated approval pathway\u201d because it is \u201csufficiently similar to Lantus to justify reliance.\u201d Lantus\u2019s patent expired in 2015 and it will be interesting to watch glargine\u2019s progress under a competing label. Another note of interest is that Basaglar is <a href=\"http:\/\/diatribe.org\/issues\/68\/new-now-next\/4\" target=\"_blank\"><em>not <\/em>approved as a biosimilar<\/a> product, as the manufacturer must actually apply for biosimilarity through a specific application process. As Merck and other companies prepare for a rollout of their own forms of insulin glargine in the coming years, we hope that choice in basal insulin therapy will increase for patients and that prices\u2026perhaps\u2026decrease.<\/p>\n<h2 style=\"text-align: justify;\"><strong>Nasal Glucagon<\/strong><\/h2>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/Locemia-device-photo-at-activation.jpg\" rel=\"mfp\"><img decoding=\"async\" class=\"aligncenter wp-image-38574 lazyload\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/Locemia-device-photo-at-activation.jpg\" alt=\"Locemia\" width=\"600\" height=\"400\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">In October, we were thrilled to learn that Eli Lilly &amp; Company <a href=\"http:\/\/www.prnewswire.com\/news-releases\/lilly-acquires-phase-iii-intranasal-glucagon-from-locemia-solutions-300157432.html\" target=\"_blank\">acquired the rights<\/a> to Montreal-based Locemia\u2019s novel nasal glucagon. Easy to carry, easy to dose, easy to implement, nasal glucagon will do for people with diabetes what the Auvi-Q has done for people with allergies \u2013 make a life-saving, every-second-counts emergency treatment fairly fool-proof to administer.<\/p>\n<p style=\"text-align: justify;\">Will we see it come to market in 2016? We hope so. Locemia had said they planned to submit to FDA in late 2015, early 2016, so it\u2019s our best guess that Lilly might follow a similar timeline.<\/p>\n<div class=\"pf-content\">\n<p class=\"p1\">\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Another insulin coming to us in 2016 is Lilly\u2019s new basal insulin, Basaglar \u2013 a form of insulin glargine (which you may recognize if you\u2019re familiar with Lantus). FDA approved it just this week after a patent dispute was finally resolved with Sanofi. <\/p>\n","protected":false},"author":21,"featured_media":38580,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"image","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1437,1441,1547],"tags":[899,381],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>7 New Diabetes Products to Look for in 2016<\/title>\n<meta name=\"description\" content=\"Looking ahead to 2016, we\u2019re optimistic about these seven diabetes products potentially hitting the market in the next 12 months.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=38567\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Melissa Lee\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=38567\",\"url\":\"https:\/\/asweetlife.org\/?p=38567\",\"name\":\"7 New Diabetes Products to Look for in 2016\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=38567#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=38567#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/7-NEW-DIABETES-PRODUCTS-TO-LOOK-FOR-IN-2016-Collage.jpg\",\"datePublished\":\"2015-12-17T14:40:31+00:00\",\"dateModified\":\"2016-07-03T07:11:16+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/62c0a4a536510e9d01359ff78b0d6c9b\"},\"description\":\"Looking ahead to 2016, we\u2019re optimistic about these seven diabetes products potentially hitting the market in the next 12 months.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=38567#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=38567\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=38567#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/7-NEW-DIABETES-PRODUCTS-TO-LOOK-FOR-IN-2016-Collage.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/7-NEW-DIABETES-PRODUCTS-TO-LOOK-FOR-IN-2016-Collage.jpg\",\"width\":2400,\"height\":1600,\"caption\":\"7 NEW DIABETES PRODUCTS TO LOOK FOR IN 2016\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=38567#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"7 New Diabetes Products to Look for in 2016\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/62c0a4a536510e9d01359ff78b0d6c9b\",\"name\":\"Melissa Lee\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f1b69d7c961cd1ee5f94c419df7a5a2c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f1b69d7c961cd1ee5f94c419df7a5a2c?s=96&d=mm&r=g\",\"caption\":\"Melissa Lee\"},\"description\":\"+Melissa Lee was diagnosed with type 1 diabetes at the age of 10 in 1990. Having spent her first 18 years post-diagnosis feeling very alone with the disease and hoping to achieve the control required for a healthy pregnancy with diabetes, Melissa discovered the diabetes online community in 2008 and found her advocacy voice, as well as the glucose control she needed to birth two healthy children. link\",\"sameAs\":[\"http:\/\/www.sweetlyvoiced.com\/\"],\"url\":\"https:\/\/asweetlife.org\/?author=21\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"7 New Diabetes Products to Look for in 2016","description":"Looking ahead to 2016, we\u2019re optimistic about these seven diabetes products potentially hitting the market in the next 12 months.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=38567","twitter_misc":{"Written by":"Melissa Lee","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=38567","url":"https:\/\/asweetlife.org\/?p=38567","name":"7 New Diabetes Products to Look for in 2016","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=38567#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=38567#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/7-NEW-DIABETES-PRODUCTS-TO-LOOK-FOR-IN-2016-Collage.jpg","datePublished":"2015-12-17T14:40:31+00:00","dateModified":"2016-07-03T07:11:16+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/62c0a4a536510e9d01359ff78b0d6c9b"},"description":"Looking ahead to 2016, we\u2019re optimistic about these seven diabetes products potentially hitting the market in the next 12 months.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=38567#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=38567"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=38567#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/7-NEW-DIABETES-PRODUCTS-TO-LOOK-FOR-IN-2016-Collage.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2015\/12\/7-NEW-DIABETES-PRODUCTS-TO-LOOK-FOR-IN-2016-Collage.jpg","width":2400,"height":1600,"caption":"7 NEW DIABETES PRODUCTS TO LOOK FOR IN 2016"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=38567#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"7 New Diabetes Products to Look for in 2016"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/62c0a4a536510e9d01359ff78b0d6c9b","name":"Melissa Lee","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f1b69d7c961cd1ee5f94c419df7a5a2c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f1b69d7c961cd1ee5f94c419df7a5a2c?s=96&d=mm&r=g","caption":"Melissa Lee"},"description":"+Melissa Lee was diagnosed with type 1 diabetes at the age of 10 in 1990. Having spent her first 18 years post-diagnosis feeling very alone with the disease and hoping to achieve the control required for a healthy pregnancy with diabetes, Melissa discovered the diabetes online community in 2008 and found her advocacy voice, as well as the glucose control she needed to birth two healthy children. link","sameAs":["http:\/\/www.sweetlyvoiced.com\/"],"url":"https:\/\/asweetlife.org\/?author=21"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/38567"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38567"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/38567\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/38580"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}